Cellular cardiomyoplasty for myocardial regeneration.
The evolving challenge of managing patients with congestive heart failure is the need to develop new therapeutic strategies. The cellular, molecular, and genetic approaches investigated aim to reinforce the weak, failing heart muscle while restoring its functional potential. This approach is principally cellular therapy (i.e. cellular cardiomyoplasty), the preferred therapeutic choice because of its clinical applicability and regenerative capacity. Different stem cells: bone marrow cells, skeletal and smooth muscle cells, vascular endothelial cells, mesothelial cells, adipose tissue stroma cells, dental stem cells, and embryonic and fetal cells, have been proposed for regenerative medicine and biology. Stem cell mobilization with G-CSF cytokine was also proposed as a single therapy for myocardial infarction. We investigated the association of cell therapy with electrostimulation (dynamic cellular cardiomyoplasty), the use of autologous human serum for cell cultures, and a new catheter for simultaneous infarct detection and cell delivery. Our team conducted cell-based myogenic and angiogenic clinical trials for chronic ischemic heart disease. Cellular cardiomyoplasty constitutes a new approach for myocardial regeneration; the ultimate goal is to avoid the progression of ventricular remodeling and heart failure for patients presenting with ischemic and non-ischemic cardiomyopathies.
Chachques
Juan C
JC
Department of Cardiovascular Surgery, Pompidou Hospital, 20 rue Leblanc, Paris 75015, France. j.chachques@brs.ap-hop-paris.fr
Salanson-Lajos
Corinne
C
Lajos
Paul
P
Shafy
Abdel
A
Alshamry
Adel
A
Carpentier
Alain
A
D018421:Cardiomyoplasty / Q000379:methods*; D002986:Clinical Trials as Topic; D006321:Heart / Q000502:physiology*; D006333:Heart Failure / Q000453:epidemiology / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D012038:Regeneration; D020257:Ventricular Remodeling / Q000502:physiology